<p></p> http://www.aidsmap.com/CROI-2009-news/page/1284757/ en-gb NAM Publications - 2012 Mon, 13 Feb 2012 21:39:53 GMT Mon, 13 Feb 2012 21:39:53 GMT http://backend.userland.com/rss RSS.NET: http://www.rssdotnet.com/ The risk of non-Hodgkin’s lymphoma developing in people with HIV within two to five years can be predicted with a high degree of accuracy using an assay already used to monitor for the development of multiple myeloma, according to findings presented on Monday at the Sixteenth Conference on Retroviruses and http://www.aidsmap.com/Test-can-predict-non-Hodgkins-lymphoma-in-people-with-HIV/page/1433362/ Canada Cancer Conferences CROI 2009 Keith Alcorn http://www.aidsmap.com/Test-can-predict-non-Hodgkins-lymphoma-in-people-with-HIV/page/1433362/ Mon, 09 Feb 2009 01:00:00 GMT A study using tenofovir and FTC (Truvada) to prevent rectal SHIV infection in monkeys – so-called pre-exposure prophylaxis (PrEP) - has shown that it is as effective for the medication to be given up to three days before exposure as it is one day before. Even giving Truvada a full http://www.aidsmap.com/PrEP-could-work-even-if-taken-several-days-in-advance/page/1433365/ Conferences CROI 2009 Transmission and prevention Gus Cairns http://www.aidsmap.com/PrEP-could-work-even-if-taken-several-days-in-advance/page/1433365/ Mon, 09 Feb 2009 01:00:00 GMT At the Sixteenth Conference on Retroviruses and Opportunistic Infections in Montreal on Monday morning, two back-to-back oral presentations affirmed that HIV is indeed often detectable in semen despite undetectable viral loads in blood plasma. The two studies found measurable HIV RNA ("viral shedding") in 3% to 14% of seminal fluid http://www.aidsmap.com/HIV-sporadically-detectable-in-semen-of-men-with-undetectable-plasma-viral-loads/page/1433378/ Conferences CROI 2009 Transmission and prevention Derek Thaczuk http://www.aidsmap.com/HIV-sporadically-detectable-in-semen-of-men-with-undetectable-plasma-viral-loads/page/1433378/ Mon, 09 Feb 2009 01:00:00 GMT Campaigners were celebrating the results of a trial of a microbicide to prevent HIV that has produced a positive result, the first one to do so. The results of the HPTN 035 were announced at the Sixteenth Conference on Retroviruses and Opportunistic Infections in Montreal today. Microbicides are chemicals that can http://www.aidsmap.com/Microbicide-reduces-HIV-infections-by-30-in-first-success-for-field/page/1433384/ Conferences CROI 2009 Malawi Microbicides South Africa Transmission and prevention Zambia Zimbabwe Gus Cairns http://www.aidsmap.com/Microbicide-reduces-HIV-infections-by-30-in-first-success-for-field/page/1433384/ Mon, 09 Feb 2009 01:00:00 GMT At the Sixteenth Conference on Retroviruses and Opportunistic Infections in Montreal on Monday morning, David Butler of the University of California San Diego presented data on four cases of male-to-male sexual transmission, showing that cell-free virus in semen – not proviral DNA in infected cells – was the means of http://www.aidsmap.com/Seminal-HIV-cell-free-virus-not-infected-cells-leads-to-transmission-between-men/page/1433387/ Conferences CROI 2009 Transmission and prevention Derek Thaczuk http://www.aidsmap.com/Seminal-HIV-cell-free-virus-not-infected-cells-leads-to-transmission-between-men/page/1433387/ Mon, 09 Feb 2009 01:00:00 GMT Antiretroviral treatment is associated with a lower risk of heterosexual HIV transmission in African serodiscordant couples, according to findings from Uganda, Rwanda and Zambia, presented on Monday at the Sixteenth Conference on Retroviruses and Opportunistic Infections. This reduction in risk has been detected despite evidence presented in the same session http://www.aidsmap.com/Antiretroviral-treatment-lowers-rates-of-HIV-transmission-in-heterosexual-couples-in-Africa/page/1433390/ Conferences CROI 2009 Rwanda Transmission and prevention Uganda Zambia Derek Thaczuk http://www.aidsmap.com/Antiretroviral-treatment-lowers-rates-of-HIV-transmission-in-heterosexual-couples-in-Africa/page/1433390/ Tue, 10 Feb 2009 01:00:00 GMT The Sixteenth Conference on Retroviruses and Opportunistic Infections heard today that two large, seven-year-long, international trials of the immune-stimulating drug interleukin-2 (IL-2, Proleukin) in people with HIV had produced a negative result. Both trials found that there was no clinical benefit in using the injectable therapy and that it produced http://www.aidsmap.com/Interleukin-2-shows-no-benefit-in-two-large-clinical-trials/page/1433395/ Conferences CROI 2009 Gus Cairns http://www.aidsmap.com/Interleukin-2-shows-no-benefit-in-two-large-clinical-trials/page/1433395/ Tue, 10 Feb 2009 01:00:00 GMT People whose viral load is well controlled on a lopinavir/ritonavir (Kaletra) regimen may see significantly improved cholesterol and triglyceride levels if they switch to raltegravir (Isentress), but at the risk of losing viral suppression, delegates to the Sixteenth Conference on Retroviruses and Opportunistic Infections heard on Monday. Raltegravir, the first-in-class integrase http://www.aidsmap.com/Switching-from-iKaletrai-to-raltegravir-improves-lipid-profiles-at-the-risk-of-viral-rebound/page/1433401/ Australia Changing treatment Conferences CROI 2009 Derek Thaczuk http://www.aidsmap.com/Switching-from-iKaletrai-to-raltegravir-improves-lipid-profiles-at-the-risk-of-viral-rebound/page/1433401/ Tue, 10 Feb 2009 01:00:00 GMT Two novel pharmacokinetic-enhancing agents - GS 9350 and SPI-425 - appear to work as well as ritonavir (Norvir) for boosting protease-inhibitor levels, but with fewer side-effects, according to presentations on Monday at the Sixteenth Conference on Retroviruses and Opportunistic Infections in Montreal. Ritonavir interferes with a liver enzyme called cytochrome P450 http://www.aidsmap.com/Two-novel-enhancer-drugs-boost-protease-inhibitors-as-much-as-ritonavir/page/1433407/ Conferences CROI 2009 New and experimental treatments Liz Highleyman http://www.aidsmap.com/Two-novel-enhancer-drugs-boost-protease-inhibitors-as-much-as-ritonavir/page/1433407/ Tue, 10 Feb 2009 01:00:00 GMT The latest follow-up data from two large cohort studies, presented on Monday at the Sixteenth Conference on Retroviruses and Opportunistic Infections in Montreal, adds further evidence that specific protease inhibitors (PIs) and nucleos(t)ide reverse transcriptase inhibitors (N(t)RTIs) are associated with a higher risk of cardiovascular problems in people with HIV. While http://www.aidsmap.com/Certain-protease-inhibitors-and-abacavir-linked-to-heart-attacks-in-two-large-cohort-studies/page/1433411/ Australia Conferences CROI 2009 Mexico Side-effects Liz Highleyman http://www.aidsmap.com/Certain-protease-inhibitors-and-abacavir-linked-to-heart-attacks-in-two-large-cohort-studies/page/1433411/ Tue, 10 Feb 2009 01:00:00 GMT